LifeStance Health Group, Inc. (LFST) Stock Price & How to Invest
Last updated November 2026
Short answer
LFST is LifeStance Health Group, one of the largest outpatient mental health providers in the United States, trading on the Nasdaq Global Select Market with a market value near ~$4.56B (shares at about $11.99 on October 16, 2026, up ~72% year to date) and trailing twelve month revenue of roughly ~$1.58B. Investors buy it as ordinary common stock through any brokerage account, and what they are buying is a payor-contracted network of roughly ~8,542 clinicians delivering therapy and psychiatry across ~33 states.
LFST stock price
As of 2026-11-16, LifeStance Health Group, Inc. (LFST) last closed at $14.48, up 131.7% over the past year. Over the past 52 weeks it has traded between $6.18 and $14.60.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or LifeStance Health Group, Inc.'s investor relations page. Walnut is informational, not investment advice.
LFST key stats
At $14.48 on November 16, 2026, LifeStance Health Group, Inc. (LFST) has a market cap of $5.5B and a P/E of 80.4 on trailing earnings (33.6 on forward earnings).
- Market cap
- $5.5B
- P/E (trailing)
- 80.4
- P/E (forward)
- 33.6
- EPS (trailing 12 months)
- $0.18
- Price to book
- 3.7
- Beta
- 1.30
Market cap, P/E and yield are measured at the $14.48 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with LifeStance Health Group, Inc. (LFST)?
The last two weeks for LifeStance Health Group, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- LFST closed at $14.48 on November 16, 2026, down 0.8% over the past five trading days (from $14.60).
- On November 12, 2026, LifeStance Health Group, Inc. filed an 8-K with the SEC reporting other events (Item 8.01). Read the 8-K on sec.gov
- On November 5, 2026, LifeStance Health Group, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 5, 2026, LifeStance Health Group, Inc. filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
- On November 6, 2026, Canaccord Genuity raised its target to $16.00 from $15.00 (Buy).
- On November 6, 2026, Keybanc raised its target to $17.00 from $15.00 (Overweight).
- On November 5, 2026, BTIG raised its target to $20.00 from $18.00 (Buy).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does LifeStance Health Group, Inc. (LFST) do?
LifeStance Health Group runs outpatient mental healthcare at national scale. Founded in 2017 and public since June 2021, the company employs licensed therapists, psychologists, psychiatrists and psychiatric nurse practitioners through its subsidiaries and supported practices, then routes patients to them through in-network insurance relationships. Care is delivered both in person and virtually, from more than ~550 centers spread across ~33 states, and volume reached roughly ~2.6 million patient visits in the second quarter of 2026 alone. Unlike cash-pay teletherapy apps, LifeStance is built around commercial insurance: about ~88% of revenue comes from commercial payors, ~7% from government programs and ~4% from self-pay, which means reimbursement rates negotiated with health plans, not consumer subscription pricing, set the revenue line.
The financial story has flipped hard. Losses ran deep for years, with net losses of roughly ~$216M in 2022 and ~$186M in 2023 as the company absorbed acquisitions, real estate and stock compensation. Since then the model has scaled into its cost base: fiscal 2025 revenue of ~$1.42B produced the first full-year profit at ~$10M, and the trailing twelve months through June 2026 show ~$1.58B of revenue, ~$51M of net income and ~$174M of free cash flow. Second quarter 2026 revenue grew ~26% year over year with adjusted EBITDA nearly doubling to ~$66M, prompting management to raise full-year guidance to ~$1.685B to ~$1.725B of revenue. The stock has rerated with it, rising about 72% year to date to near $12 by mid-October 2026, and investors are weighing that inflection against a valuation near ~92 times trailing earnings (about ~28 times forward), concentrated payor exposure, and a sponsor base at TPG and Summit Partners still holding about ~35.4% of the stock. The next checkpoint is third-quarter 2026 results on November 5, 2026, where consensus expects about ~$432M of revenue and ~$0.08 of EPS.
What's driving LifeStance Health Group, Inc. (LFST)?
1. Clinician headcount plus productivity, compounding together
Revenue in this model is close to clinicians multiplied by visits multiplied by rate per visit. LifeStance grew its clinician base ~11% year over year to ~8,542 while visit volumes rose ~19%, meaning existing clinicians are also seeing more patients. Both levers moving at once is what produced ~26% revenue growth in the second quarter of 2026 against ~11% a year earlier. Consensus for the third quarter of 2026 calls for about ~$432M of revenue, roughly flat sequentially with the second quarter's ~$435M, and full-year 2026 revenue of about ~$1.71B, inside management's raised range.
2. Operating leverage on a largely fixed center and corporate base
Center Margin, the company's measure of revenue less direct center costs, reached ~35.2% of revenue in the second quarter versus ~31.4% a year earlier. General and administrative spending grew far slower than revenue, so adjusted EBITDA margin widened from ~9.8% to ~15.2%. Whether that expansion continues depends on holding center costs flat as a share of revenue while volumes climb.
3. Reimbursement rates and payor negotiation
Higher total revenue per visit was cited as a direct driver of the growth, which reflects renegotiated in-network rates rather than volume alone. Payors have historically underpriced behavioral health, and parity enforcement plus documented shortages of mental health clinicians give a network of this size leverage at the table. Rate is also the most fragile input: two commercial payors alone accounted for ~15% and ~14% of revenue in the quarter.
4. Cash generation funding buybacks instead of dilution
Free cash flow of roughly ~$174M over the trailing twelve months changed the capital story. The board authorized a fresh ~$100M repurchase program in August 2026 replacing an identical February authorization, and ~13.0 million shares were bought back for ~$97.6M during the first half. Share count fell from ~388.3 million to ~382.0 million, a reversal after years in which stock compensation steadily expanded it.
What are the risks to LifeStance Health Group, Inc. (LFST)?
Payor concentration is the sharpest exposure: two commercial insurers each represented roughly ~14% to ~15% of revenue, so a single unfavorable contract renegotiation or a reimbursement policy shift can compress the rate per visit that drives margin expansion. Valuation leaves little cushion after a ~138% one-year run, with the stock near ~92 times trailing earnings, ~28 times forward earnings and ~37 times EV to EBITDA on a business whose GAAP net margin is about ~3%, meaning a growth deceleration toward the ~11% pace of 2025 would be poorly received. Legal and regulatory matters are ongoing rather than resolved: a privacy class action captioned Strong v. LifeStance Health Group, filed April 26, 2023 over the use of website pixel tracking technologies, is settling for roughly ~$3.0 million with a final approval hearing scheduled for October 2026 (the outcome was not yet reported in the sources reviewed for this October 16 update), and the June 2021 IPO drew a securities class action in 2022 that is no longer disclosed as a pending matter in the company's Legal Proceedings item. Healthcare providers of this scale also carry standing exposure to fraud and abuse statutes, retroactive payor audits and state licensure rules across all ~33 states of operation. Financial leverage is moderate but real, with roughly ~$276M of term loan principal outstanding at SOFR plus ~3.00% maturing in December 2029 under a net leverage covenant, and TPG and Summit Partners together still hold about ~35.4% of the shares, an overhang that can weigh on the stock whenever those holders trim. Insider selling is routine but visible: the chief technology officer sold 42,067 shares for about ~$541K in September 2026.
What is the LifeStance Health Group, Inc. (LFST) forecast?
10 analysts publish price targets on LFST, averaging $16.30 as of November 2026, or +12.6% against the $14.48 share price on November 16, 2026. The published targets run from $12.00 to $20.00, a moderate spread, and the ratings split 9 buy, 2 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full LFST forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is LFST a buy or a sell?
We give no verdict on LifeStance Health Group, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Clinician headcount plus productivity, compounding together. Revenue in this model is close to clinicians multiplied by visits multiplied by rate per visit. The most optimistic published target, $20.00, assumes this works close to its best case.
The case against. Payor concentration is the sharpest exposure: two commercial insurers each represented roughly ~14% to ~15% of revenue, so a single unfavorable contract renegotiation or a reimbursement policy shift can compress the rate per visit that drives margin expansion. The most pessimistic target, $12.00, is roughly what LFST is worth if this bites instead.
Read the full bull and bear case on LFST, including what would have to change to break either one. Walnut is not an investment adviser.
Has LifeStance Health Group, Inc. (LFST) split its stock?
No. LifeStance Health Group, Inc. (LFST) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is LifeStance Health Group, Inc. (LFST) valued?
Market cap, P/E and dividend yield at today's price are in the LFST key stats above. The business figures below come from LifeStance Health Group, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$1.58B (Q2 2026 +26% YoY)
- Net income (TTM): ~$51M, or ~$0.13 per share
- Gross / operating margin: ~34% / ~7%
- Free cash flow (TTM): ~$172M
As of October 2026: Pricing reflects the inflection rather than the trailing profit: the shares are up ~72% in 2026, yet forward earnings estimates (~$0.36 for 2026, ~$0.43 for 2027) put the multiple near ~28x rather than the ~92x trailing GAAP figure, and the gap is mostly stock compensation, amortization and litigation costs. Against full-year 2026 adjusted EBITDA guidance of ~$215M to ~$235M, enterprise value works out to roughly ~21x the midpoint. Cash of ~$226M against ~$276M of term loan principal leaves the balance sheet close to neutral, and analysts' mean target sits near ~$14.40 with a buy consensus.
Who competes with LifeStance Health Group, Inc. (LFST)?
Public behavioral health providers
Acadia Healthcare (ACHC) operates inpatient psychiatric and addiction treatment facilities, a heavier asset base serving more acute patients than LifeStance's outpatient model. Talkspace (TALK) sells virtual therapy and has pushed into insurance and Medicare coverage, competing for the same in-network dollar at a fraction of the revenue scale. Teladoc Health (TDOC) reaches consumers through BetterHelp, largely cash-pay, plus employer and health plan behavioral offerings.
Private clinician networks and payor-owned behavioral arms
Headway, Alma and Grow Therapy connect independent therapists to insurance panels without employing them, a capital-light structure competing directly for clinician supply. Spring Health and Lyra Health sell behavioral benefits to employers. Optum Behavioral Health, inside UnitedHealth, is simultaneously one of the largest payors and one of the largest providers, which makes it both a customer and a rival.
Physician practice consolidators
Investors often compare LifeStance to other roll-ups of outpatient providers, including Privia Health (PRVA) in primary care enablement, agilon health (AGL) in value-based primary care, and US Physical Therapy (USPH) in outpatient rehabilitation. All face the same core test: whether acquiring and integrating clinician practices produces durable margin, or whether the economics stay with the clinicians and the payors.
What stocks are similar to LifeStance Health Group, Inc. (LFST)?
Other names that sit close to LFST: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in LifeStance Health Group, Inc. (LFST)
There are three common ways to get LFST exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LFST sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where LFST fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on LifeStance Health Group, Inc. (LFST)
LifeStance has turned a long-unprofitable clinician roll-up into a business generating real cash, and the open question is whether ~26% revenue growth and mid-teens adjusted margins can hold long enough to justify a multiple that already prices in years of compounding. The market has leaned toward yes in 2026: the stock is up about 72% year to date and about 138% over one year as of October 16, 2026, which raises the bar for the third-quarter report due November 5.
More on LifeStance Health Group, Inc. (LFST)
Whether LFST is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LFST a buy or a sell?, and where the stock could go from here in the LFST stock forecast.
For income investors, whether LFST pays a dividend and how the payout looks is covered in does LFST pay a dividend? And to weigh LFST against a peer, read the full side-by-side comparisons: LFST vs ACHC and LFST vs TDOC.
Wondering how LFST fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about LifeStance Health Group, Inc.
Ask Walnut's AI anything about LFST and see how it fits what you own.
FAQ
What does LifeStance Health actually do?
+
It provides outpatient mental healthcare, meaning therapy, psychiatry and psychological testing for children, adolescents, adults and older patients. Care is delivered virtually and in person across more than ~550 centers in ~33 states by roughly ~8,542 licensed clinicians, and most of it is billed to commercial insurance rather than paid out of pocket.
How do you invest in LFST?
+
Shares trade on the Nasdaq Global Select Market under the symbol LFST, so any US brokerage account that supports listed equities can buy them. Brokers offering fractional shares let you size a position by dollar amount instead of share count. LifeStance pays no dividend and has said it does not anticipate paying one, so the entire return depends on the share price.
Is LifeStance profitable?
+
Yes, recently. After net losses of roughly ~$216M in 2022, ~$186M in 2023 and ~$57M in 2024, the company posted its first full-year GAAP profit of about ~$10M in 2025. Trailing twelve month net income through June 2026 reached ~$51M on ~$1.58B of revenue, a net margin near ~3%, alongside ~$174M of free cash flow.
Why is the P/E ratio so high?
+
GAAP earnings are small relative to the business because stock-based compensation, acquisition amortization and litigation costs sit between revenue and net income. Roughly ~$51M of trailing net income against a ~$4.56B market cap produces a multiple near ~92 as of October 16, 2026; on 2027 consensus EPS of ~$0.43 the forward multiple is about ~28. Measured against guided 2026 adjusted EBITDA of ~$215M to ~$235M, the enterprise value works out closer to ~21x.
Who are LifeStance's biggest customers?
+
Health insurers, not patients directly. Commercial payors accounted for about ~88% of revenue in the second quarter of 2026, government programs ~7%, and self-pay ~4%. Two individual commercial payors each exceeded 10% of revenue, at roughly ~15% and ~14%, which concentrates a meaningful share of the top line in a small number of contract negotiations.
Is LifeStance buying back stock?
+
It is. The board approved a ~$100M repurchase authorization in August 2026, replacing an identical program approved in February 2026. During the first half of 2026 the company repurchased ~13.0 million shares for about ~$97.6M, and shares outstanding fell from ~388.3 million at year end 2025 to ~382.0 million at June 30, 2026.
What are the main legal or regulatory matters?
+
A privacy class action, Strong v. LifeStance Health Group, filed April 26, 2023 over website pixel tracking, is being settled for roughly ~$3.0 million with a final approval hearing set for October 2026. A securities class action tied to the 2021 IPO was filed in 2022 and is not disclosed as pending in the current Legal Proceedings item. Broader healthcare fraud and abuse rules and payor audit rights apply continuously.
How much debt does LifeStance carry?
+
Roughly ~$276M of principal was outstanding at June 30, 2026 under a December 2024 credit agreement, comprising a term loan maturing December 19, 2029 plus a ~$100M revolver, priced at SOFR plus about ~3.00% with leverage-based stepdowns and a maximum total net leverage covenant. Cash of ~$226M offsets most of it, leaving net long-term debt the company reported at about ~$259M.
How did LifeStance do in its latest quarter?
+
In the second quarter of 2026 (ended June 30), revenue rose ~26% year over year to ~$435M and net income reached ~$23.6M. EPS of ~$0.11 beat the ~$0.08 consensus, the third beat in four quarters, and management raised full-year revenue guidance to ~$1.685B to ~$1.725B. Third-quarter results are scheduled for November 5, 2026, with consensus at ~$0.08 EPS on ~$432M of revenue.
How has LFST stock performed in 2026?
+
Strongly. As of the October 16, 2026 close near $11.99, LFST was up about 72% year to date and about 138% over one year, inside a 52-week range of roughly $4.77 to $13.56. It has eased about 5% over the past month as the shares consolidated ahead of the November 5 earnings report.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with LifeStance Health Group, Inc.'s investor relations page or your broker before making investment decisions.